Davide Bosso

642 total citations
18 papers, 366 citations indexed

About

Davide Bosso is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Davide Bosso has authored 18 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Davide Bosso's work include Prostate Cancer Treatment and Research (8 papers), Multiple Myeloma Research and Treatments (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Davide Bosso is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Multiple Myeloma Research and Treatments (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Davide Bosso collaborates with scholars based in Italy, United States and Canada. Davide Bosso's co-authors include Piera Federico, Bruno Daniele, Margaret Ottaviano, Mario Rosanova, Carlo Buonerba, Sabino De Placido, Giuseppe Di Lorenzo, Antonia Silvestri, Antonietta Fabbrocini and Pasqualina Giordano and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Davide Bosso

18 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Davide Bosso Italy 12 167 133 132 70 57 18 366
Karen Giselle Chee United States 7 163 1.0× 102 0.8× 182 1.4× 36 0.5× 65 1.1× 9 380
Rodrigo Ruiz-Soto United States 9 90 0.5× 174 1.3× 186 1.4× 37 0.5× 66 1.2× 19 408
Dilara Akhoundova Switzerland 12 118 0.7× 148 1.1× 247 1.9× 113 1.6× 28 0.5× 45 425
M. D’Arcangelo Italy 12 196 1.2× 119 0.9× 200 1.5× 79 1.1× 22 0.4× 31 360
Karel Cwiertka Czechia 10 123 0.7× 115 0.9× 247 1.9× 108 1.5× 40 0.7× 45 436
Alexander B. Sibley United States 12 80 0.5× 124 0.9× 171 1.3× 71 1.0× 23 0.4× 27 393
Zuoxing Niu China 9 103 0.6× 163 1.2× 152 1.2× 112 1.6× 55 1.0× 40 376
Corrado Gallo Stampino Italy 12 103 0.6× 183 1.4× 238 1.8× 58 0.8× 20 0.4× 31 419
Mahmoud Ould-Kaci France 10 245 1.5× 125 0.9× 429 3.3× 73 1.0× 42 0.7× 17 540
Hironori Betsunoh Japan 11 112 0.7× 153 1.2× 103 0.8× 70 1.0× 22 0.4× 24 362

Countries citing papers authored by Davide Bosso

Since Specialization
Citations

This map shows the geographic impact of Davide Bosso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davide Bosso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davide Bosso more than expected).

Fields of papers citing papers by Davide Bosso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davide Bosso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davide Bosso. The network helps show where Davide Bosso may publish in the future.

Co-authorship network of co-authors of Davide Bosso

This figure shows the co-authorship network connecting the top 25 collaborators of Davide Bosso. A scholar is included among the top collaborators of Davide Bosso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davide Bosso. Davide Bosso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ottaviano, Margaret, Emilio Francesco Giunta, Laura Marandino, et al.. (2022). Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. Biomedicines. 10(1). 150–150. 21 indexed citations
2.
Giunta, Emilio Francesco, Marcello Curvietto, Davide Bosso, et al.. (2021). Epigenetic Regulation in Melanoma: Facts and Hopes. Cells. 10(8). 2048–2048. 29 indexed citations
3.
Petrillo, Angelica, Emilio Francesco Giunta, Davide Bosso, et al.. (2021). Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. Journal of Clinical Medicine. 10(8). 1777–1777. 12 indexed citations
4.
Ottaviano, Margaret, Emilio Francesco Giunta, Marcello Curvietto, et al.. (2021). BRAF Gene and Melanoma: Back to the Future. International Journal of Molecular Sciences. 22(7). 3474–3474. 62 indexed citations
5.
Ottaviano, Margaret, Emilio Francesco Giunta, Pasquale Rescigno, et al.. (2021). The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. International Journal of Molecular Sciences. 22(13). 7160–7160. 8 indexed citations
6.
Federico, Piera, Angelica Petrillo, Pasqualina Giordano, et al.. (2020). Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers. 12(10). 3025–3025. 67 indexed citations
7.
Buonerba, Carlo, Pasquale Dolce, Martina Pagliuca, et al.. (2019). Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers. 11(9). 1259–1259. 17 indexed citations
8.
Buonerba, Carlo, Davide Bosso, Sabino De Placido, & Giuseppe Di Lorenzo. (2018). A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.. Journal of Clinical Oncology. 36(6_suppl). TPS387–TPS387. 1 indexed citations
9.
Buonerba, Carlo, Davide Bosso, Sabino De Placido, & Giuseppe Di Lorenzo. (2017). A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE. Annals of Oncology. 28. v292–v293. 2 indexed citations
10.
Bosso, Davide, Martina Pagliuca, Guru Sonpavde, et al.. (2017). PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Medicine. 96(24). e6817–e6817. 6 indexed citations
11.
Lorenzo, Giuseppe Di, Sergio Bracarda, Donatello Gasparro, et al.. (2016). Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine. 95(2). e2299–e2299. 12 indexed citations
12.
Lorenzo, Giuseppe Di, Martina Pagliuca, Teresa Perillo, et al.. (2016). Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. Medicine. 95(14). e2754–e2754. 2 indexed citations
13.
Lorenzo, Giuseppe Di, Sabino De Placido, Martina Pagliuca, et al.. (2016). The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opinion on Biological Therapy. 16(11). 1387–1401. 28 indexed citations
14.
Placido, Sabino De, Pasquale Rescigno, Piera Federico, et al.. (2014). Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World Journal of Clinical Cases. 2(6). 228–228. 17 indexed citations
15.
Buonerba, Carlo, Piera Federico, Davide Bosso, et al.. (2014). Carboplatin Plus Etoposide in Heavily Pretreated Castration-Resistant Prostate Cancer Patients. Future Oncology. 10(8). 1353–1360. 23 indexed citations
16.
Buonerba, Carlo, Gregory R. Pond, Guru Sonpavde, et al.. (2013). Potential Value of Gleason Score in Predicting the Benefit of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 9(6). 889–897. 31 indexed citations
17.
Perri, Francesco, Franco Ionna, Paolo Muto, et al.. (2013). Induction docetaxel-cisplatin followed by extended-field radiotherapy in patients with cervical metastases from unknown primary carcinoma.. PubMed. 33(3). 1135–9. 3 indexed citations
18.
Lorenzo, Giuseppe Di, Carmine D’Aniello, Carlo Buonerba, et al.. (2012). Peg-filgrastim and cabazitaxel in prostate cancer patients. Anti-Cancer Drugs. 24(1). 84–89. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Giselle Chee Breakdown of academic impact, for papers by Rodrigo Ruiz-Soto Breakdown of academic impact, for papers by Dilara Akhoundova Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Karel Cwiertka Breakdown of academic impact, for papers by Alexander B. Sibley Breakdown of academic impact, for papers by Zuoxing Niu Breakdown of academic impact, for papers by Corrado Gallo Stampino Breakdown of academic impact, for papers by Mahmoud Ould-Kaci Breakdown of academic impact, for papers by Hironori Betsunoh
Rankless by CCL
2026